ReviewCurrent atherosclerosis reports2014
Antiplatelet strategies for secondary prevention of stroke and TIA.
Review in Current atherosclerosis reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.The Cochrane database of systematic reviews · 2022Pooled it
- Leukoaraiosis: Epidemiology, Imaging, Risk Factors, and Management of Age-Related Cerebral White Matter Hyperintensities.Journal of stroke · 2024Review
- Association between Antiplatelet Therapy and Changes in Intraplaque Hemorrhage in Patients with Mild to Moderate Symptomatic Carotid Stenosis: A Longitudinal MRI Study.Cerebrovascular diseases (Basel, Switzerland) · 2024Observational
- New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease.Clinical science (London, England : 1979) · 2019Review
- Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study.Influenza and other respiratory viruses · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is a major public health issue, and stroke recurrence accounts for a quarter of all events. Antiplatelet therapy has been extensively studied for secondary stroke prevention and is established as effective in this high-risk population. Several agents have been evaluated in this setting, both in isolation and combination. The most widely used antiplatelet medications are aspirin, clopidogrel, and aspirin plus extended-release dipyridamole. However, new agents and combinations continue to be evaluated. A detailed review of the evidence supporting various antiplatelet regimens for secondary stroke prevention is outlined with special focus on recent developments that may impact clinical management of patients with stroke or TIA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.